Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia: A Single-arm Phase 2 Trial

BACKGROUND: Venetoclax with hypomethylating agents is a new standard of care for newly diagnosed (ND) patients with acute myeloid leukemia (AML) who are 75 years or older, or unfit for intensive chemotherapy. Pharmacodynamic studies have suggested superiority of the longer 10-day regimen of decitabi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Lancet Haematol
Autori principali: DiNardo, Courtney D., Maiti, Abhishek, Rausch, Caitlin R., Pemmaraju, Naveen, Naqvi, Kiran, Daver, Naval G., Kadia, Tapan M., Borthakur, Gautam, Ohanian, Maro, Alvarado, Yesid, Issa, Ghayas C., Montalban-Bravo, Guillermo, Short, Nicholas J., Yilmaz, Musa, Bose, Prithviraj, Jabbour, Elias J., Takahashi, Koichi, Burger, Jan, Garcia-Manero, Guillermo, Jain, Nitin, Kornblau, Steven M., Thompson, Philip A., Estrov, Zeev, Masarova, Lucia, Sasaki, Koji, Verstovsek, Srdan, Ferrajoli, Alessandra, Weirda, William G., Wang, Sa A., Konopleva, Sergej, Chen, Zhining, Pierce, Sherry A., Ning, Jing, Qia, Wei, Ravandi, Farhad, Andreeff, Michael, Welch, John S., Kantarjian, Hagop M., Konopleva, Marina Y.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549397/
https://ncbi.nlm.nih.gov/pubmed/32896301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(20)30210-6
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi